<DOC>
	<DOC>NCT00152451</DOC>
	<brief_summary>This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.</brief_summary>
	<brief_title>Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<criteria>Males/Females from 18 to 65 years of age (minimum body weight of 40 kg) Subjects with a confirmed diagnosis of epilepsy suffering from partial onset seizures whether or not secondarily generalized. Subjects who have been treated for epilepsy for â‰¥6 months and are currently uncontrolled while being treated with 13 concomitant AED(s). Female subjects without childbearing potential; Female subjects with childbearing potential are eligible if they use a medically accepted nonhormonal contraceptive method Seizures occurring in clusters. Status epilepticus within 6 months of Visit 1. History of nonepileptic seizures Subjects on vigabatrin Subjects on felbamate, unless treatment has been continuous for &gt;2 years Ongoing psychiatric disease other than mild controlled disorders. Subjects with clinically significant organ dysfunction Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients Pregnant or lactating women. Subjects currently taking levetiracetam (LEV). Use of benzodiazepines (for any indication) taken at a higher frequency than an average of once a week, unless counted as one of the concomitant AEDs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Epilepsy: partial onset seizures, seletracetam</keyword>
</DOC>